rs3748079 — ITPR3 ITPR3 rs3748079

Promoter variant in the ITPR3 calcium channel gene affecting NKX2.5 binding and immune cell calcium signaling, associated with lupus, Graves' disease, and rheumatoid arthritis risk

See your personal result for ITPR3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ITPR3 rs3748079 — When Calcium Signaling Fails the Immune System

Calcium is the language of immune activation. When a T cell or B cell encounters its target antigen, a burst of intracellular calcium acts as the trigger for the immune response — switching on gene programs that drive proliferation, cytokine release, and antibody production. The ITPR3 gene encodes the inositol 1,4,5-trisphosphate receptor type 311 inositol 1,4,5-trisphosphate receptor type 3
IP3R3 is a calcium release channel on the endoplasmic reticulum membrane; it opens in response to IP3, a second messenger generated after immune receptor activation, one of the principal channels that mediates this calcium surge in lymphocytes. A common variant in the ITPR3 promoter — rs3748079 — quietly alters how much of this channel is produced, with consequences that ripple across several autoimmune conditions.

The Mechanism

The rs3748079 variant lies approximately 2 kilobases upstream of the ITPR3 transcription start site, squarely in the promoter region that controls how much ITPR3 protein a cell makes. The key functional difference between alleles is whether the transcription factor NKX2.522 NKX2.5
NKX2.5 is a homeodomain transcription factor originally characterized in heart development but expressed in lymphocytes and other tissues can bind to this region. Oishi et al. demonstrated33 Oishi et al. demonstrated
Electrophoretic mobility shift assay confirmed NKX2.5 protein binds specifically to the T allele sequence and not the C allele sequence at rs3748079 that NKX2.5 binds exclusively to the T allele sequence. The T allele creates a consensus NKX2.5 binding motif; the C allele disrupts it.

When NKX2.5 binds — which only happens in T allele carriers — it likely acts as a transcriptional repressor at this promoter site, dampening ITPR3 expression. Counterintuitively, this reduced channel expression appears protective against autoimmunity. C allele carriers (the majority) have unrestrained ITPR3 expression, which may amplify calcium signaling in lymphocytes and lower the threshold for immune activation. The net result is a background state of slightly heightened immune reactivity that predisposes to aberrant self-attacks.

ITPR3 sits within the MHC class III region44 MHC class III region
The major histocompatibility complex on chromosome 6p21 contains three classes of genes: class I (antigen presentation), class II (T cell help), and class III (complement, cytokines, other immune genes). ITPR3 is a class III neighbor. of chromosome 6p21 — the immune gene-dense stretch that harbors HLA alleles and dozens of other autoimmune susceptibility loci. This proximity means rs3748079 associations must be carefully evaluated for linkage disequilibrium with neighboring MHC variants, though Lambertucci et al. found the ITPR3 contribution to type 1 diabetes was statistically distinct from MHC class II effects55 statistically distinct from MHC class II effects
Regression analysis showed ITPR3 effect was independent of HLA-DR/DQ genotype in the Swedish T1D cohort.

The Evidence

The most comprehensive study comes from Oishi et al. 200866 Oishi et al. 2008
Case-control study of rs3748079 in two independent Japanese cohorts; total sample sizes not specified in abstract but p-values in the 10⁻⁸ range indicate thousands of subjects, who tested rs3748079 across three autoimmune diseases in Japanese populations. For SLE, the association was striking: odds ratio 1.88 (95% CI 1.51–2.35, p=1.78×10⁻⁸) for the risk genotype. Graves' disease showed OR 1.57 (95% CI 1.22–2.02), and rheumatoid arthritis OR 1.23 (95% CI 1.05–1.43). The replication across independent cohorts within the same study strengthens confidence in the associations.

The interaction finding is particularly notable: individuals carrying risk variants at both ITPR3 and NKX2.5 loci77 NKX2.5 loci
NKX2.5 has independent genetic variants associated with SLE; the combined effect when both loci carry risk alleles reached OR=5.77, suggesting the two proteins act in the same pathway simultaneously showed a combined SLE odds ratio of 5.77 — far exceeding what either locus contributes alone. This gene-gene interaction confirms that the NKX2.5–ITPR3 transcriptional regulatory axis is a genuine biological pathway, not just a statistical artifact.

For type 1 diabetes, Lambertucci et al. 200688 Lambertucci et al. 2006
High-resolution 3 kb-interval SNP mapping across the ITPR3 locus in 1,124 Swedish subjects; most significant association at an intronic SNP (p=1.30×10⁻⁶) identified ITPR3 as a T1D susceptibility locus with recessive OR of 2.5 and an estimated population-attributable risk of 21.6% in Sweden — a substantial contribution from a single locus. The most associated variant in that study was intronic rather than rs3748079 specifically, but the overlapping disease profile across studies points to ITPR3's general role in autoimmune susceptibility.

An important limitation: most published work is in East Asian (Japanese) and Scandinavian populations. Independent replication in diverse ancestries is limited, and the ancestry-specific allele frequencies differ substantially (T allele at ~4% in Africans versus ~25–30% in South Asians). Effects in non-East Asian populations should be treated with greater caution.

Practical Actions

For CC genotype carriers (the majority), awareness of modestly elevated risk for SLE, Graves' disease, and RA is the main takeaway. These diseases share a pattern of chronic inflammation and autoantibody production. Early symptom recognition — joint pain, unexplained fatigue, skin rashes (especially butterfly rash for SLE), thyroid dysfunction signs, dry eyes or mouth — enables faster diagnosis. The association with type 1 diabetes (primarily identified in European populations) adds metabolic monitoring to the relevant domains.

Because ITPR3 regulates calcium signaling, environmental factors that modulate immune calcium flux — such as vitamin D status99 vitamin D status
Vitamin D receptor signaling inhibits IP3-mediated calcium release in T cells, suggesting vitamin D sufficiency could modulate ITPR3-dependent immune activation; population data link low vitamin D to elevated SLE and RA risk and omega-3 fatty acid intake affecting membrane fluidity around calcium channels — may be particularly relevant to managing baseline immune tone in at-risk carriers. However, these connections are mechanistically plausible rather than directly proven for this specific variant.

Interactions

ITPR3 rs3748079 shows documented interaction with NKX2.5 variants. The combined risk (OR=5.77 for SLE) when both ITPR3 and NKX2.5 carry risk alleles is substantially greater than either alone, suggesting that NKX2.5 genetic variation modulates the functional consequence of the ITPR3 promoter variant. Since NKX2.5 is the transcription factor whose binding to the T allele confers protection, variants that reduce NKX2.5 expression or function would eliminate this protective effect even in T allele carriers.

The rs2229634 SNP in ITPR3 (a coding region variant) has been separately associated with Kawasaki disease complications and cervical cancer susceptibility in haplotype analysis with rs3748079. These SNPs may act in concert to regulate both ITPR3 expression and function, though the combined effects on autoimmune conditions have not been fully characterized.

ITPR3's location in the MHC class III region means its genetic effects should be interpreted in the context of an individual's full HLA profile. High-risk HLA haplotypes (HLA-DR3/4-DQ8 for T1D, HLA-DRB1 shared epitope for RA, HLA-DR2/3 for SLE) and ITPR3 risk alleles likely operate through distinct but converging mechanisms affecting immune tolerance.

Genotype Interpretations

What each possible genotype means for this variant.

TT Protective Genotype Normal

Two copies of the protective T allele — reduced ITPR3 promoter activity and lower autoimmune risk

You carry two copies of the T allele at rs3748079, which creates a binding site for the NKX2.5 transcription factor in the ITPR3 promoter. This dampens ITPR3 expression in immune cells, moderating the calcium signals that drive lymphocyte activation. Population studies in Japanese cohorts show this genotype confers the lowest risk for SLE, Graves' disease, and rheumatoid arthritis among the three possible genotypes. Only about 4% of people globally carry this genotype (and closer to 6% in European and South Asian populations), making it relatively uncommon.

CT Intermediate Risk Intermediate

One risk and one protective allele — modestly elevated autoimmune susceptibility

The additive inheritance pattern of rs3748079 means heterozygous CT carriers show intermediate effects between the two homozygous genotypes. One functional NKX2.5 binding site (from the T allele) partially restrains ITPR3 expression, but the C allele's contribution to unrestrained promoter activity offsets this. The Oishi 2008 study confirmed additive dose-response effects across the three genotypes for SLE and Graves' disease. The absolute risk increase above population baseline is modest — SLE has a population prevalence of roughly 0.05-0.2%, and even doubling this risk represents a small absolute number. The key practical value is awareness that early inflammatory symptoms warrant prompt investigation rather than a "wait and see" approach.

CC Higher Autoimmune Risk High Risk

Two copies of the risk allele — higher ITPR3 expression and elevated susceptibility to lupus, Graves' disease, and RA

The biological basis of the CC risk involves the NKX2.5 transcriptional regulatory axis. The T allele creates a DNA sequence that NKX2.5 protein can bind; the C allele disrupts this motif. In T allele carriers, NKX2.5 binding in the ITPR3 promoter acts as a brake, reducing ITPR3 channel expression. In CC homozygotes, this brake is absent, and ITPR3-mediated calcium release in response to immune stimuli is likely amplified. Higher intracellular calcium after antigen receptor activation lowers the threshold for T-cell and B-cell responses, potentially allowing more vigorous reactions to weak self-antigens that would normally be ignored.

The interaction with NKX2.5 variants is particularly important to note: Oishi et al. found that CC genotype combined with NKX2.5 risk variants produced an SLE odds ratio of 5.77 — exceeding the product of individual effects, suggesting genuine pathway-level synergy. If you have access to your NKX2.5 genotype data, discussing the combined result with an immunologist would provide a fuller risk picture.

Disease associations for this variant are best established in Japanese and East Asian populations. European studies (particularly the Swedish T1D work) corroborate ITPR3's role, but the specific contribution of rs3748079 in European ancestry individuals is less characterized.